Acurx Pharmaceuticals, INC 10-Q quarterly reports

Acurx Pharmaceuticals reports Q1 2026 results, focusing on ibezapolstat development and ongoing financing efforts.

Acurx Pharmaceuticals reported significantly reduced net losses and increased cash reserves for the nine months ended September 30, 2025, while regaining Nasdaq compliance.

Acurx Pharmaceuticals reported a significant reduction in net loss and increased cash, but faces substantial doubt about its ability to continue as a going concern and Nasdaq listing compliance issues.

Acurx Pharmaceuticals announces its Q1 2025 financial results, highlighting a net loss of $2.1 million and a new $12 million purchase agreement with Lincoln Park Capital.

Acurx Pharmaceuticals reported a net loss of $2.8 million for the third quarter of 2024, while continuing to advance its lead antibiotic candidate, ibezapolstat.

Acurx Pharmaceuticals reported a net loss of $4.1 million for the second quarter of 2024, while continuing to advance its lead antibiotic candidate, ibezapolstat.

Acurx Pharmaceuticals reported a net loss of $4.4 million for the first quarter of 2024, while highlighting positive clinical trial results for its lead antibiotic candidate, ibezapolstat.